Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -46.36M | -41.63M | -35.39M | -31.37M | -30.04M |
| Total Depreciation and Amortization | 347.00K | 336.00K | 302.00K | 260.00K | 227.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.22M | 5.16M | 4.28M | 3.55M | 2.79M |
| Change in Net Operating Assets | -1.88M | 183.00K | -1.97M | 164.00K | 257.00K |
| Cash from Operations | -41.67M | -35.95M | -32.78M | -27.40M | -26.77M |
| Capital Expenditure | -340.00K | -411.00K | -924.00K | -841.00K | -613.00K |
| Sale of Property, Plant, and Equipment | -- | 3.00K | 3.00K | 3.00K | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.64M | -54.64M | -78.21M | -78.21M | 15.10M |
| Cash from Investing | -35.98M | -55.05M | -79.14M | -79.05M | 14.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.38M | -2.20M | -3.03M | -3.30M | -3.30M |
| Issuance of Common Stock | 94.00M | 93.94M | 95.04M | 109.08M | 15.17M |
| Repurchase of Common Stock | -74.00K | -121.00K | -121.00K | -47.00K | -47.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -133.00K | -69.00K | -119.00K | -- | -- |
| Cash from Financing | 92.42M | 91.54M | 91.78M | 105.73M | 11.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.76M | 540.00K | -20.14M | -722.00K | -461.00K |